UBS Maintains Buy on Sarepta Therapeutics, Raises Price Target to $167
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow maintains a Buy rating on Sarepta Therapeutics (NASDAQ:SRPT) and raises the price target from $164 to $167.
March 01, 2024 | 4:48 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UBS analyst Colin Bristow maintains a Buy rating on Sarepta Therapeutics and raises the price target from $164 to $167.
The increase in price target by a reputable analyst like Colin Bristow from UBS is a positive signal for investors, indicating a bullish outlook on Sarepta Therapeutics. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100